VolitionRx is a multinational epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential not only to prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. VolitionRx is primarily focused on human diagnostics but also has a subsidiary focused on animal
In this video, Cameron Reynolds, President and Chief Executive Officer of VolitionRx, discusses the company’s full-year 2019 results and provides a business update. During 2019, the company made very strong progress in assay and platform development, with its Nu.Q™ Capture programme and epigenetic toolkit, its Nu.Q™ Vet collaboration with Texas A&M University and, most recently, with the acquisition of the epigenetics reagents company, Octamer.
Volition strengthened its balance sheet with existing investors exercising over $16m of outstanding warrants to purchase shares of common stock. It ended the quarter with cash and cash equivalents of $17m. During the fourth quarter, the company was awarded a further $3.3m in non-dilutive funding, bringing the total non-dilutive funding (grants and loans) to more than $7.5m to date.